Whole Genome Bisulfite Sequencing Market Size, Share and Trends Analysis, By Product and Service (Instruments, Reagents & Kits, Software, and Services), By Application (Epigenetics Research, Cancer Research & Oncology, Developmental Biology, Neurological Disorders Research, Agricultural & Plant Epigenetics, and Infectious Disease Research), By End-Use, and By Region, Forecast 2025-2032

Whole Genome Bisulfite Sequencing Market Overview and Key Insights:

The whole genome bisulfite sequencing market size reached USD 288.8 million in 2024 and is expected to register a revenue CAGR of 17.7% during the forecast period. Whole-genome bisulfite sequencing (WGBS) is a high-resolution sequencing technology used to determine the methylation state of cytosine bases in DNA molecules. It is becoming a more accessible method, with applications ranging from fundamental to disease research.

Market Drivers:

Rising prevalence of cancer and neurological disorders is a key driver of revenue growth in the whole genome bisulfite sequencing market. According to the World Health Organization (WHO), depression affects an estimated 3.8% of the population, including 5% of adults (4% male and 6% female) and 5.7% of persons over the age of 60. Globally, over 280 million people suffer from depression. Depression is approximately 50% more common in women than in males. More than 10% of pregnant and postpartum women worldwide suffer from depression. Each year, more than 700,000 people die by suicide. Suicide is the fourth highest cause of death among people aged 15 to 29 years.

Growing demand for epigenetics research is another key driver driving the market growth over the forecasted period. Due to next-generation sequencing (NGS) technology developments, researchers may now explore DNA methylation across the entire genome. The most extensively used technology for assessing DNA methylation is whole genome bisulfite sequencing (WGBS). Bisulfite conversion of DNA followed by high-throughput sequencing permits detection of DNA methylation at a single CpG resolution, and it has fast become the preferred approach in DNA methylation research. Data from whole-genome BS-seq (WGBS) experiments allow for the comparison of genome-wide DNA methylation profiles across different biological contexts.

On January 2025, New England Biolabs (NEB) has announced the release of EM-seq v2, a high-performance enzyme-based alternative to bisulfite sequencing for detecting 5mC and 5hC.  The enzyme-based conversion procedures for EM-seq and E5hmC-seq eliminate the drawbacks of whole genome bisulfite treatment, such as DNA damage, which causes fragmentation, loss, and bias.  The newly upgraded kit provides increased performance for a larger input range (100 pg to 200 ng) as well as a faster, more streamlined procedure when compared to the original EM-seq kit.

Market Opportunity:

Emerging acts as an opportunity for the whole genome bisulfite sequencing market. Epigenetics is important in personalized medicine because it provides insights into the complex terrain of neurological and mental illnesses.  The dynamic nature of the epigenome, which is influenced by both internal and external environmental variables, opens the possibility of using customized medicine to diagnose and treat these epigenetic issues.  Thus, epigenetic biomarkers of disease and therapeutic response, as well as current and future pharmaceuticals with epigenetic modes of action, present prospects for individualized therapy regimens tailored to each patient’s unique epigenetic landscape.

Recent Trends:

Emerging trends include advancements in sequencing technologies, integration with single-cell and spatial epigenetic analysis, expansion into biomarker research and precision medicine, and adoption of advanced bioinformatics tools.

DNA methylation is an important biological marker for cellular differentiation and cell-specific activities. Single-cell whole genome DNA methylation profiling approaches have considerable potential for resolving the DNA methylation signatures of specific cell types. Single-cell transcriptome and methylome sequencing allow for the simultaneous assessment of gene expression and DNA methylation variation, as well as the research of their association.

On November 2024, Wasatch Biolabs (WBL), a disruptive R&D and high-throughput clinical laboratory, has announced a collaboration with Oxford Nanopore Technologies (ONT), a company that provides a new generation of nanopore-based molecular sensing technology, to create a Direct Whole Methylome Sequencing product that addresses key limitations of traditional bisulfite sequencing and methylation microarrays. It provides exquisite single-molecule resolution and allows for simultaneous detection of DNA sequence, methylation, and hydroxymethylation patterns.

Restraints & Challenges:

Complexity of data interpretation is a key restraint limiting the growth of the market. Incomplete bisulfite treatment is a significant challenge in methylation detection approaches.  Incomplete conversion sometimes causes researchers to overestimate the quantity of methylation in a sample.  Another problem for bisulfite-based methylation investigations is the DNA sample’s susceptibility to deterioration during protracted incubation phases. The treatment of DNA with sodium bisulfite efficiently transforms the genome into three bases (A, G, and U/T), except for a few methylated cytosines. As a result, it is extremely challenging to accurately match short sequence reads to their original chromosomal position.

Product and Service Segment Insights and Analysis:

Based on the product and service, the whole genome bisulfite sequencing market is segmented into instruments, reagents & kits, software, and services.

Instruments segment contributed the largest market revenue share in 2024, primarily driven by high-throughput, cost-effective, and accurate methylation sequencing. Advancements of NGS technologies and long read sequencing are expanding research applications and accelerating the adoption of WGBS in clinical and translation research. Advanced sequencing instruments enable researchers to study methylation landscapes in embryonic development and neurodegenerative disorders.

On October 2024, PacBio, a leading producer of high-quality and highly accurate sequencing solutions, has launched SPRQ, an enhanced sequencing chemical for their Revio long-read sequencing machine. Paired instrument software updates will also improve methylation calling accuracy and enable detection of novel types of methylation marks, providing customers with a comprehensive, multiomic view of each sample.

Services segment is expected to have the highest growth rate throughout the forecasted period, providing researchers and clinicians with cost-effective, scalable, and expert-driven solutions for DNA methylation analysis. Many research institutions, hospitals, and biotech companies prefer to outsource WGBS to specialized service providers instead of investing in expensive sequencing instruments. Service providers offer highly optimized workflows, bioinformatics analysis, and technical expertise, ensuring high-quality results without the need for in-house specialists.

Application Segment Insights and Analysis:

Based on the application, the whole genome bisulfite sequencing market is segmented into epigenetics research, cancer research & oncology, developmental biology, neurological disorders research, agricultural & plant epigenetics, and infectious disease research.

Cancer research & oncology segment contributed the largest market revenue share in 2024. According to the American Cancer Society, in the United States, it is estimated that around 22,010 persons will be diagnosed with acute myeloid leukemia (AML) by 2025.  Most cases will be in adults, with an estimated 11,090 persons dying from AML.  Again, the most of these deaths will be in adults.  AML makes up approximately one-third of all leukaemia’s in adulthood. AML can occur in children; however, it is uncommon in those under the age of 45. The average age of people when they are first diagnosed with AML is about 69.

On November 2024, Oxford Nanopore Technologies, the company that delivers a new generation of nanopore-based molecular sensing technology, announced a new collaboration with UK Biobank to create the world’s first comprehensive, large-scale epigenetic dataset. The project will use Oxford Nanopore’s information-rich DNA/RNA sequencing technology to map the epigenome of 50,000 participant samples to unlock crucial insights into disease mechanisms and improve patient outcomes.

Agricultural & plant epigenetics are expected to have the highest market growth rate throughout the forecasted period. Investigations into the role of DNA methylation in nutrient uptake and stress responses have revealed its potential to enhance nutrient use efficiency in crops, thereby reducing reliance on chemical inputs. For instance, under nitrogen-deficient conditions, certain plants improve nitrogen absorption by modifying the methylation status of key genes, offering a novel strategy for breeding nutrient-efficient crop varieties.

End-Use Segment Insights and Analysis:

Based on the end-use, the whole genome bisulfite sequencing market is segmented into academic & research institutions, biotechnology & pharmaceutical companies, clinical & diagnostic laboratories, and Contract Research Organizations (CROs).

Biotechnology & pharmaceutical companies segment contributed the largest market share in 2024. These organizations leverage DNA methylation analysis for drug discovery, biomarker development, and precision medicine. Growing use of WGBS in clinical research, to validate epigenetic biomarkers and novel drug targets. They also partner with sequencing providers to incorporate DNA methylation analysis in multi-omics data. The demand for epigenetic biomarkers, targeted therapies, and companion diagnostics is fuelling investments in WGBS technology.

On April 2023, Biomodal (previously Cambridge Epigenetix) commercialized its novel duet multiomics solution, which demonstrates the combinatorial power of genetic and epigenetic information from a single low volume sample. The duet multiomics solution is the world’s first single-base-resolution sequencing technique, allowing for the simultaneous phased reading of genetic and epigenetic information in a single sample, with a single process and any sequencer. The hardware-agnostic solution extracts additional epigenetic information from a single low input DNA library without requiring costly, resource-intensive analytics or harsh chemical treatment.

Geographical Outlook:

Whole genome bisulfite sequencing market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Whole Genome Bisulfite Sequencing Market:

North America is registered to have highest market share in whole genome bisulfite sequencing market in 2024. This is mainly due to the rising prevalence of cancer, neurological disorders, and cardiovascular disorders and advancements in Next-Generation Sequencing (NGS) technologies. According to the Centre of Disease Control and Prevention (CDC), in 2022, 702,880 people died from heart disease, accounting for one in every five deaths. Cardiovascular disease kills one person every 33 seconds, and a heart attack occurs every 40 seconds in the United States. Each year, approximately 805,000 people have a heart attack in the United States, with 605,000 having their first heart attack and 200,000 having had one previously.

On September 2024, the National Institutes of Health (NIH) has provided USD 5.4 million in first-year funding to launch a new program that promotes the integration of genetics into learning health systems.  The new Genomics-enabled Learning Health System (gLHS) Network seeks to explore and advance techniques for incorporating genetic information into existing learning health systems.

Asia Pacific Whole Genome Bisulfite Sequencing Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period driven by growing demand for epigenetics research. According to the United Nations, youth are defined as those who are between the ages of 15 and 24. In India, 10% of the population is in this age group. According to UNICEF, one in seven of these young people always feel depressed or have little interest in doing anything. This suggests that mental health issues are very common among this group, which can have detrimental long-term effects on their general well-being and quality of life.

On October 2023, Cardio Diagnostics Holdings, Inc., a pioneer in artificial intelligence-driven precision cardiovascular medicine tests, announced a significant step toward transforming global cardiovascular health by signing a Supply and Distribution Agreement with Aimil Ltd., one of India’s leading organizations.

Competition Analysis:

The whole genome bisulfite sequencing market is characterized by a fragmented structure, with several players competing across various segments and regions. List of major players included in the whole genome bisulfite sequencing market report are:

• CD Genomics
• BGI
• Eurofins Genomics
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Zymo Research
• QIAGEN
• Agilent Technologies
• Hologic Inc.
• New England Biolabs
• Merck KGaA
• Creative Biolabs
• Nucleome Informatics
• Singulomics Corporation
• Novogene Co., Ltd

Strategic Developments in Whole Genome Bisulfite Sequencing Market:

• In February 2024, Integrated DNA Technologies (IDT) and Element Biosciences, Inc. have expanded their collaboration to provide more efficient and streamlined next generation sequencing (NGS) workflows for users of the AVITI System, an innovative sequencing and multi-omics platform built on Element’s novel avidity base chemistry. These products are suitable for a wide range of applications, including DNA, RNA, and methylation sequencing procedures, as well as IDT’s well-established hybridization capture chemical.
• In December 2024, two researchers at the Harry Perkins Institute of Medical Research have been awarded separate federal government grants totaling USD 3.6 million to improve illness understanding and treatment. The study was financed by the National Health and Medical Research Council’s Investigator Grants scheme, which is a significant investment in Australia’s health and medical research workforce. The 2024 Investigator Grants cycle contains USD 35 million in grants to strengthen assistance for early and mid-career researchers.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of The Whole Genome Bisulfite Sequencing Market Report:

The Whole Genome Bisulfite Sequencing market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Product and Service Outlook (Revenue, USD Million; 2022-2032)
  • Instruments
  • Reagents & Kits
    • DNA Extraction & Purification Kits & Reagents
    • PCR & Amplification Kits & Reagents
    • Sequencing Kits & Reagents
    • Bisulfite Conversion Kits & Reagents
    • Library Preparation Kits & Reagents
  • Software
    • DNA Methylation Analysis Tools
    • Cloud-Based Bioinformatics Solutions
  • Services

• Application Outlook (Revenue, USD Million; 2022-2032)
  • Epigenetics Research
  • Cancer Research & Oncology
  • Developmental Biology
  • Neurological Disorders Research
  • Agricultural & Plant Epigenetics
  • Infectious Disease Research

• End-Use Outlook (Revenue, USD Million; 2022-2032)
  • Academic & Research Institutions
  • Biotechnology & Pharmaceutical Companies
  • Clinical & Diagnostic Laboratories
  • Contract Research Organizations (CROs)

• Regional Outlook (Revenue, USD Million; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the Whole Genome Bisulfite Sequencing market report